^
Association details:
| Biomarker: | JAK2 mutation |
|---|---|
| Cancer: | Leukemia |
| Drug: | Jakafi (ruxolitinib) (JAK2 inhibitor, JAK1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Ruxolitinib and Chemotherapy in Adolescents and Young Adults With Ph-like Acute Lymphoblastic Leukemia
Excerpt:
...- Cytokine receptor-like factor 2 (CRLF2) rearranged (JAK2 mutant or wild-type)...
Trial ID:
Source:
Title:
Ruxolitinib Phosphate and Decitabine in Treating Patients With Relapsed or Refractory or Post Myeloproliferative Acute Myeloid Leukemia
Excerpt:
...Maximum Tolerated Dose of Ruxolitinib Phosphate (Phase I)`Number of Participants With a Response (Complete Response [CR] + CR With Incomplete Blood Count Recovery) (Phase 2)`Number of Participants With Post-MPN Acute Myeloid Leukemia (AML) With JAK2 Mutations (Phase 2)...
Trial ID:
More C2 evidence
Source:
Title:
A Phase 2 Study of Ruxolitinib With Chemotherapy in Children With Acute Lymphoblastic Leukemia
Excerpt:
...CRLF2 rearrangement with confirmed JAK1 or JAK2 mutation (JAK+) 2....
Trial ID:
Source:
Title:
An open-label, multicenter study of INC424 monotherapy or in combination with azacitidine for patients with post-myeloproliferative disorders (MPD) – AML or with CMML Eine offene, multizentrische Studie mit INC424 als Monotherapie oder in Kombination mit Azacitidin für Patienten mit AML (akute myeloische Leukämi) als Folge einer myeloproliferativen Erkrankung oder mit CMML (chronische myelomonozytäre Leukämie)
Excerpt:
...Patients must be diagnosed with postmyeloproliferative AML according to the 2008 World Health Organization criteria (Appendix A), irrespective of JAK2 mutation status or diagnosed with CMML with a white-blood-cell count above 13×10⁹ cells /L.2. ...
Trial ID:
Source:
Title:
Ruxolitinib for Patients With Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)
Excerpt:
...elevated b2-microglobulin levels (defined as 2 times compared to normal), carry a JAK2 mutation, or presence of phosphorylated p65 NF-kB component in at least 5% of bone marrow cells....
Trial ID:
Source:
Title:
Ruxolitinib in Treating Patients With Hypereosinophilic Syndrome or Primary Eosinophilic Disorders
Excerpt:
...- Subjects with JAK2 mutations are included within this group....
Trial ID:
Less C2 evidence
Source:
Title:
RUXOLITINIB AND VITAMIN K ANTAGONISTS(VKA) IS SAFE AND EFFECTIVE AND SHOWS A FASTER RECANALIZATION AND AN ANTINFLAMMATORY EFFECT IN PRIMARY MYELOFIBROSIS(PMF) WITH SPLANCHNIC VEIN THROMBOSIS(SVT).
Published date:
05/17/2018
Excerpt:
4 female patients, median age 47 (R35-55), with PMF INT-2 and with SVT (2 portal, 2 mesenteric + splenic + portal), median Hb11.5g/dl (R11-12.5), PLT90000/mcl (R70000-100000), WBC10000/mcl (R4000-11000), peripheral blood blasts 1% (R1-2), 1 patient heterozygous for factor V Leiden received ruxolitinib 20mg/day +warfarin. All patients were Jak-2 mutated(GROUP1)...Patients of GROUP1 showed a complete resolution of SVT in 2 cases and a partial portal recanalization in 2 cases after 3 months, without any thrombosis relapse or progression after 6 months...Ruxolitinib and VKA is safe and effective and shows a faster recanalization and an antinflammatory effect in patients with PMF with SVT.
